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Abstract
Aim: Evaluation of the diagnostic accuracy of stress perfusion cardiovascular magnetic resonance for the diagnosis of 
significant obstructive coronary artery disease (CAD) through meta-analysis of the available data.
Methodology: Original articles in any language published before July 2009 were selected from available databases 
(MEDLINE, Cochrane Library and BioMedCentral) using the combined search terms of magnetic resonance, perfusion, 
and coronary angiography; with the exploded term coronary artery disease. Statistical analysis was only performed on 
studies that: (1) used a [greater than or equal to] 1.5 Tesla MR scanner; (2) employed invasive coronary angiography as 
the reference standard for diagnosing significant obstructive CAD, defined as a [greater than or equal to] 50% diameter 
stenosis; and (3) provided sufficient data to permit analysis.
Results: From the 263 citations identified, 55 relevant original articles were selected. Only 35 fulfilled all of the inclusion 
criteria, and of these 26 presented data on patient-based analysis. The overall patient-based analysis demonstrated a 
sensitivity of 89% (95% CI: 88-91%), and a specificity of 80% (95% CI: 78-83%). Adenosine stress perfusion CMR had 
better sensitivity than with dipyridamole (90% (88-92%) versus 86% (80-90%), P = 0.022), and a tendency to a better 
specificity (81% (78-84%) versus 77% (71-82%), P = 0.065).
Conclusion: Stress perfusion CMR is highly sensitive for detection of CAD but its specificity remains moderate.
Introduction
Perfusion cardiovascular magnetic resonance (CMR) is
an emerging technique for the detection of coronary
artery disease (CAD). The technique is attractive because
of its non-invasive nature and safe characteristics, and
might potentially play a major role in future diagnosis and
risk stratification guidelines for patients with suspected
CAD. Several small studies have evaluated the diagnostic
performance of stress perfusion CMR and some of those
have been included in a previous meta-analysis [1]. In the
current study we provide a comprehensive and contem-
porary meta-analysis of its diagnostic accuracy compared
with an invasive coronary angiography (CA) used as a ref-
erence standard.
Methods
Search strategy
Using the combined medical subject headings (MeSH) of
magnetic resonance, perfusion, and coronary angiography,
with the exploded terms coronary artery disease; the
MEDLINE, Cochrane Library and BioMedCentral data-
bases were searched independently by two investigators
(MH, GF) for all publications, in any language, before July
2009. In addition, the published reference lists of these
articles were systematically searched.
Study eligibility
The search results were collated by the same two investi-
gators (MH, GF), and duplicate or overlapping papers
removed. Studies were eligible if: [1] stress perfusion
CMR was used as a diagnostic test for significant obstruc-
tive CAD; [2] conventional invasive CA was used as the
reference standard for diagnosing significant obstructive
CAD, defined as a ≥50% diameter stenosis; and [3] the
absolute numbers of true positive (TP), false positive
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(FP), true negative (TN), and false negative (FN) were
reported, or could be derived. Studies were excluded if
they were performed with a 0.5 or 1 Tesla MR scanner, if
they included less than 10 patients, and if only abstracts
from scientific meetings were published as the data pro-
vided may either be not sufficiently detailed or finalized.
Any disagreements on eligibility were resolved by discus-
sion and consensus between the two investigators.
Data extraction and quality assessment
Data extraction was performed independently by the two
investigators (MH, GF) for each study. The following
fields were recorded: study population size; gender distri-
bution; mean age and standard deviation; number of
patients with documented CAD; prevalence of CAD; rel-
ative timing of the two imaging procedures; the degree of
blinding in interpretation of test results (both to the
patient's clinical context and the results of the other
imaging modality); type and brand of MR machine used;
the type of perfusion stressor (adenosine, nicorandil,
dipyridamole), and the number of side effects; the dose
and injection rate of Gadolinium administrated; and the
modality of MR image analysis (visual, or semi-quantita-
tive). Any discrepancies were resolved by discussion and
consensus between the two investigators. Where avail-
able, data was recorded separately at the level of coronary
territories and coronary arteries. The study quality con-
formed to the Quality Assessment of Studies of Diagnos-
tic Accuracy included in Systematic Reviews guidelines
[2]. In one study, for which patients were evaluated both
with 1.5 and 3T CMR, we used 1.5 T data in the meta-
analysis. For the studies where analysis was performed
with both 50% and 70% coronary stenosis definitions, we
i ncl uded r es ults  wit h t h e 70%  definit i on in t he  pool ed
reported sensitivity and specificity.
Data synthesis and statistical analysis
Data analysis was performed at the level of the patient,
the coronary territory and the coronary artery. Sensitivity
and specificity were calculated using the TP, TN, FP, and
FN rates [3,4]. From these were calculated the likelihood
ratios, which express how much the odds of significant
obstructive CAD change in the presence of either an
abnormal stress perfusion CMR (positive likelihood ratio:
PLR = sensitivity/(1- specificity)), or a normal stress per-
fusion CMR (negative likelihood ratio: NLR = (1- sensi-
tivity)/specificity). Finally, the ratio of the PLR to the NLR
was used to calculate the diagnostic odds ratio (DOR),
which estimates how much greater the odds of having
significant obstructive CAD are for patients with a posi-
tive test result compared with a negative one.
All these measures of diagnostic accuracy were calcu-
lated for each individual study and reported as point esti-
m a t e s  w i t h  9 5 %  c o n f i d e n c e  i n t e r v a l s .  T h e y  w e r e  t h e n
combined using a random-effects model and each point
estimate weighted by the inverse of the sum of its vari-
ance and the between-study variance. We also assessed
between-study statistical heterogeneity using the
Cochran Q chi-square tests (cut off for statistical signifi-
cance P ≤ .10). Since diagnostic parameters are, by defini-
tion, interdependent, independent weighting may
sometimes give spurious results and provide biased esti-
mates; to overcome the interdependence problem, we
computed the weighted symmetric summary receiver
operating characteristic curve, with pertinent areas under
the curve, using the Moses-Shapiro-Littenberg method
[5-7]. All statistical calculations were performed with
SPSS 14.0 (SPSS, Chicago, IL) and Meta-DiSc [8], and sig-
nificance testing was at the two-tailed 0.05 level [9].
Results
Database and literature searches retrieved 263 citations,
amongst which 55 relevant publications were identified
(Figure 1). Further scrutiny led 20 papers to be rejected
either because of overlapping data, or exclusion criteria
were met (employed 0.5 or 1 T CMR, or inclusion criteria
were absent (impossible to find or calculate absolute fig-
ures from presented data). Therefore, 35 studies were
finally included in the meta-analysis [10-44], all of which
had been published between 2000 and 2009. Study and
population characteristics are summarized in Table 1,
and the results of the pooled analyses are summarized in
Table 2. Dose of contrast Gadolinium administrated
range from 0.025 to 0.15 mmol/kg, with an injection rate
varying from 3 to 10 mL/s. Quality assessments for all
included studies are shown in Table 3. The 35 papers eli-
gible for the analyses comprised 2,456 patients, and of the
2,154 patients for whom gender and the age were speci-
Figure 1 Flow diagram of the reviewing process.
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Table 1: Characteristics of included studies
Authors Year Brand Tesla Patients (n) Excluded (n) Male (%) Mean Age (SD) Prevalence 
(% per patient)
Coronary 
Stenosis (%)
Stressor* Side Effects ** (n) Data assessment
Al Saadi, (10) 2000 Philips 1.5 40 6 - - 100 ≥ 75 D 0 1/2 Quantitative
Schwitter (11) 2001 GE 1.5 48 1 83 59(-) 79 ≥ 50 D 0 1/2 Quantitative
Ibrahim, (12) 2002 Philips 1.5 25 0 76 63(13) 100 > 75 A - 1/2 Quantitative
Sensky (13) 2002 Siemens 1.5 30 0 90 62(-) 100 > 50 A 0 Visual
Chiu, (14) 2003 Siemens 1.5 13 0 54 68(-) 92 > 50 A 0 Visual
Doyle (15) 2003 Philips 1.5 229 45 0 59(11) 14 ≥ 70 D - 1/2 Quantitative
Ishida (16) 2003 GE 1.5 104 0 78 66(12) 74 > 70 D 0 Visual
Nagel (17) 2003 Philips 1.5 90 6 81 63(8) 51 ≥ 75 A 2 1/2 Quantitative
Bunce (18) 2004 Picker 1.5 35 0 77 56(12) 49 ≥ 50 A 0 1/2 Quantitative
Giang (19) 2004 GE 1.5 94 14 69 58(-) 65 ≥ 50 A 0 1/2 Quantitative
Kawase (20) 2004 Philips 1.5 50 0 58 66(12) 66 ≥ 70 N 0 Visual
Paetsch (21) 2004 Philips 1.5 79 0 66 61(9) 67 > 50 A 0 Visual
Plein (22) 2004 Philips 1.5 72 4 79 57(11) 82 ≥ 70 A 1 Visual
Takase (23) 2004 GE 1.5 102 - 83 66(9) 74 > 50 D - Visual
Thiele (24) 2004 Philips 1.5 20 0 - 64(8) 90 ≥ 70 A 0 1/2 Quantitative
Okuda (25) 2005 GE 1.5 33 0 88 60(-) 97 ≥ 75 D 0 Visual
Plein (26) 2005 Philips 1.5 92 10 74 58(-) 72 > 70 A 0 1/2 Quantitative
Sakuma (27) 2005 Siemens 1.5 40 0 70 65(9) 52 > 70 D 0 Visual
Cury (28) 2006 GE 1.5 47 1 81 63(5) 65 ≥ 70 D - Visual
Klem (29) 2006 Siemens 1.5 100 8 49 58(11) 40 >50/≥ 70 A 1 Visual
Pilz (30) 2006 GE 1.5 176 5 63 62(12) 66 > 70 A 2 Visual
Rieber (31) 2006 Siemens 1.5 50 7 88 61(8) 67 > 50 A 0 1/2 Quantitative
Cheng (32) 2007 Siemens 1.5/3 65 4 75 64(8) 66 ≥ 50 A 1 Visual
Costa (33) 2007 Siemens 1.5 37 7 53 65(11) 97 > 50/> 70 A 0 1/2 Quantitative
Greenwood (34) 2007 Philips 1.5 35 0 89 55(-) 83 ≥ 70 A 0 Visual
Kühl (35) 2007 Philips 1.5 20 1 68 64(13) 100 ≥ 50 A 0 1/2 Quantitative
Merkle (36) 2007 Philips 1.5 228 0 79 61(11) 75 > 50/> 70 A 0 Visual
Seeger (37) 2007 Siemens 1.5 51 0 86 65(9) 74 > 70 A 0 1/2 Quantitative
Gebker (38) 2008 Philips 3 101 3 70 62(8) 69 ≥ 50 A 2 Visual
Meyer (39) 2008 Philips 3 60 0 63 59(10) 60 ≥ 70 A 0 Visual
Pilz (40) 2008 GE 1.5 22 0 64 66(12) 33 ≥ 70 A 0 Visual
Klein (41) 2008 Philips 1.5 54 5 65 60(10) 47 ≥ 50 A 2 Visual
Klem (42) 2008 Siemens 1.5 147 11 0 63(11) 27 ≥ 70 A 0 Visual
Thomas (43) 2008 Philips 3 60 0 68 - 47 ≥ 50 A 0 Visual
Burgstahler (44) 2008 Philips 1.5 23 3 65 68(12) 40 ≥ 70 A 0 Visual
* Stressor: A (Adenosine); D (Dypirydamole); N (Nicorandil) ** n: significant side effects, which led to stop the MR exam.Hamon et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:29
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fied, 1,481 were males (68.7%) and the mean age was 61.3
years.
Diagnostic performance of stress perfusion CMR: Patient-
based analysis
Overall per-patient analysis results pooled from 26 stud-
ies (2,125 patients) demonstrated a sensitivity of 89%
(95% CI: 88-91%), a specificity of 80% (95% CI: 78-83%), a
PLR of 4.18 (3.31-5.27), a NLR of 0.15 (95% CI: 0.11-0.20),
a DOR of 33.65 (95% CI: 22.09-51.27), and an AUC of
0.92 (Figures 2, 3, 4, 5, 6). Statistical heterogeneity was
observed for all relevant diagnostic performance mea-
sures. The per-patient prevalence of CAD was 57% (1,205
of 2,125 patients).
With adenosine as the stressor (20 studies, 1,658
patients) the results were: a sensitivity of 90% (88-92%), a
specificity of 81% (78-84%), a PLR of 4.47 (3.39-5.88), a
NLR of 0.14 (0.11-0.18), a DOR of 37.17 (25.16-54.91),
and an AUC of 0.93. Statistical heterogeneity was
observed for all relevant diagnostic performance mea-
sures. With dipyridamole as the stressor (5 studies, 417
patients), the results were: a sensitivity of 86% (80-90%), a
specificity of 77% (71-82%), a PLR of 2.97 (2.16-4.09), a
NLR of 0.20 (0.09-0.45), a DOR of 17.03 (5.56-52.18), and
an AUC of 0.84. Statistical heterogeneity was observed
for all relevant diagnostic performance measures, except
specificity and positive likelihood ratio. ROC curves for
stress perfusion CMR performed with adenosine or
dipyridamole are shown in Figure 7.
A sensitivity analysis was carried out based on the
equipment used (3 Tesla, and 1.5 Tesla MRI). For 3 Tesla
(4 studies, 282 patients), results were: a sensitivity of 92%
(87-95%), a specificity of 78% (69-85%), a PLR of 3.96
(2.78-5.63), a NLR of 0.12 (0.07-0.20), and a DOR of 35.74
(17.13-74.53). For 1.5 Tesla (23 studies, 1,904 patients),
results were: a sensitivity 89% (87-91%), a specificity of
80% (78-83%), a PLR of 4.26 (3.26-5.55), a NLR of 0.15
(0.11-0.20), and a DOR of 34.25 (21.26-55.17).
Diagnostic performance of stress perfusion CMR: Coronary 
territory and coronary artery-based analysis
Per-territory results, pooled from 17 studies correspond-
ing to 2,709 coronary territories, demonstrated a sensitiv-
ity of 82% (79-84%), a specificity of 84% (82-85%), a PLR
of 4.90 (3.66-6.55), a NLR of 0.23 (0.20-0.27), and a DOR
of 23.23 (18.33-29.45). At the territory level heterogeneity
was significant for all relevant diagnostic performance
measures except sensitivity, negative likelihood ratio and
diagnostic odd ratios.
Per-artery analysis pooled 8 datasets and demonstrated
for left anterior descending artery (LAD), circumflex
artery (CX) and right coronary artery (RCA), respec-
tively, sensitivities of 83%, 76% and 78% and specificities
of 83%, 87%, and 87%. Statistical heterogeneity was
Table 2: Pooled summary results
Studies N studies N Sensitivity Specificity Positive 
Likelihood ratio
Negative 
likelihood ratio
Diagnostic odds 
ratio
Per Patient analysis (all) 26 2125 Patients 89% (88-91) 80% (78-83) 4.18 (3.31-5.27) 0.15 (0.11-0.20) 33.65 (22.09-51.27)
Adenosine stressor 20 1658 Patients 90% (88-92) 81% (78-84) 4.47 (3.39-5.88) 0.14 (0.11-0.18) 37.17 (25.16-54.91)
Dipyridamole stressor 5 417 Patients 86% (80-90) 77% (71-82) 2.97 (2.16-4.09) 0.20 (0.09-0.45) 17.03 (5.56 - 52.18)
Visual assessment 20 1624 Patients 91% (89-93) 79% (76-83) 4.08 (3.15-5.29) 0.13 (0.10-0.17) 36.79 (23.90-56.63)
Semi-quant. assessment 6 501 Patients 82%(77-87) 82% (77-86) 4.88 (2.62-9.09) 0.22 (0.13-0.37) 25.44 (8.90-72.70)
Per Territory analysis 17 2709 Territories 82% (79-84) 84% (82-85) 4.90(3.66-6.55) 0.23 (0.20-0.27) 23.23 (18.33-29.45)
Per Artery analysis
LAD 8 662 Arteries 83%(78-88) 83%(79-86) 4.37(2.96-6.44) 0.22 (0.16-0.31) 21.42 (10.94-41.94)
CX 8 672 Arteries 76%(70-82) 87%(84-90) 5.74(3.94-8.35) 0.30 (0.23-0.38) 22.25 (14.09-35.10)
RCA 8 657 Arteries 78%(71-84) 87% (83-90) 5.58 (3.74-8.32) 0.29 (0.21-0.38) 23.07 (14.55-36.57)Hamon et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:29
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Table 3: Quality assessment (QUADAS)
Study Item 1 Item 2 Item 3 Item 4 Item 5 Item 6 Item 7 Item 8 Item 9 Item 10 Item 11 Item 12 Item 13 Item 14
Al Saadi, 2000 (10) no yes yes unclear yes yes yes no no unclear unclear no yes yes
Schwitter, 2001 (11) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Ibrahim, 2002 (12) yes yes yes unclear yes yes yes yes Yes unclear unclear yes yes yes
Sensky, 2002 (13) yes yes yes unclear yes yes yes yes Yes yes yes yes yes yes
Chiu, 2003 (14) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Doyle, 2003 (15) yes yes yes unclear yes yes yes yes Yes no no yes yes yes
Ishida,2003 (16) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Nagel, 2003 (17) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Bunce, 2004 (18) yes yes yes yes yes yes yes yes Yes yes yes yes no yes
Giang, 2004 (19) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Kawase, 2004 (20) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Paetsch, 2004 (21) yes yes yes unclear yes yes yes yes Yes yes yes yes unclear unclear
Plein, 2004 (22) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Takase, 2004 (23) yes yes yes yes yes yes yes yes Yes yes yes yes no unclear
Thiele,2004 (24) yes yes yes no yes yes yes yes Yes yes yes yes yes yes
Okuda,2005 (25) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Plein, 2005 (26) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Sakuma,2005 (27) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Cury, 2006 (28) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Klem, 2006 (29) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Pliz, 2006 (30) yes yes yes unclear yes yes yes yes Yes yes yes yes yes yes
Rieber, 2006 (31) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Cheng, 2007 (32) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Costa,2007 (33) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Greenwood, 2007 (34) no yes yes yes yes yes yes yes Yes yes yes yes yes yes
Kuhl, 2007 (35) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Merkle, 2007 (36) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Seeger, 2007 (37) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Gebker, 2008 (38) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Meyer, 2008 (39) yes yes yes yes yes yes yes yes Yes yes yes yes unclear unclear
Pilz, 2008 (40) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Klein,2008 (41) yes yes yes yes yes yes yes yes Yes yes yes yes yes yes
Klem, 2008 (42) no yes yes yes yes yes yes yes Yes yes yes yes yes yes
Thomas, 2008 (43) yes yes yes unclear yes yes yes yes Yes yes yes yes yes unclear
Burgstahler,2008 (44) yes yes yes unclear yes yes yes yes Yes unclear unclear yes yes yes
Item 1: was the spectrum of patients representative of the patients who will receive the test in practice?; Item 2: were selection criteria clearly 
described?; Item 3: is the reference standard likely to correctly classify the target condition?; Item 4: is the time period between reference and 
standard and index test short enough to be reasonably sure that the target condition did not change between the two tests?; Item 5: did the whole 
sample or a random selection of the sample, receive verification using a reference standard of diagnosis?; Item 6: did patients receive the same 
reference standard regardless of the index test results?; Item 7: was the reference standard independent of the index test (i.e. the index test did 
not form part of the reference standard); Item 8: was the execution of the index test described in the sufficient detail to permit replication of the 
test; Item 9: was the execution of the reference standard described in the sufficient detail to permit its replication?; Item 10: were the index test 
results interpreted without knowledge of the results of the reference standard?; Item 11: were the reference standard results interpreted without 
knowledge of the results of the index test?; Item 12: were the same clinical data available when test results were interpreted as would be available 
when the test is used in practice?; Item 13: were uninterpretable/intermediate test results reported?; Item 14: were withdrawals from the study 
explained.Hamon et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:29
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observed for all the performance measurements except
sensitivity and negative likelihood ratio for LAD and CX,
and diagnostic odds ratio for CX.
Discussion
This meta-analysis showed stress perfusion CMR to have
a high sensitivity (89%) and a moderate specificity (80%)
at patient level for the diagnosis of significant obstructive
CAD in patients with high prevalence of CAD (57%). We
included twelve more studies (on stress perfusion CMR)
than the previous meta-analysis by Nandalur et al. [1],
which showed a similar diagnostic performance with a
pooled sensitivity and specificity of respectively 90% and
81% from 14 perfusion studies. A high false positive rate
could have driven the relatively low specificity, and may
be due to perfusion defects caused by: [1] dark rim arte-
facts, the hypo-intensities along the endocardial border
of the left ventricular myocardium seen during first-pass
transit of a MR contrast medium, thought to be due to a
combination of the gadolinium bolus, motion and resolu-
tion [45]; [2] the presence of microvascular disease; and
[3] spontaneous or therapeutic re-opening of a coronary
artery supplying an area of myocardial infarction that has
persistent microvascular obstruction [28,32].
Alternatively, because CA detects luminal morphology
rather than the functional significance of a stenosis, a
false positive CMR results may in fact represent a 'false
negative' angiogram in the context of angiographically
'invisible' small vessel disease capable of inducing suben-
docardial ischemia [40]. This potential source of error
could be minimised if the hemodynamic significance of
an epicardial coronary artery stenosis were to be deter-
mined by the measurement of the fractional flow reserve
(FFR) during CA. If validated, this may represent a better
reference standard than CA alone. However, although
three studies found there to be a good correlation
between the performance of stress perfusion CMR and
CA with FFR measurement [31,33,35], sufficient data was
not present to evaluate its accuracy in this study.
Another point to outline is that for some studies
[11,17,19], different decision thresholds to diagnose per-
fusion CMR as abnormal were appraised: for these stud-
ies, the reported sensitivity and specificity could be
considered as optimistic because the end points was cho-
sen retrospectively.
In addition, there was a large range of contrast doses
used in the individual studies, with the dose of gadolin-
ium administered in the included studies varying by 6-
fold, with dose ranging from 0.025 to 0.15 mmole/kg.
Although currently there is no consensus regarding the
optimal dose and injection rates for perfusion CMR, two
multicenter dose-ranging studies have evaluated the
impact of contrast dose on the performance of perfusion
CMR using a visual analysis [46,47]. In the first, Wolff et
al. considered a low dose of 0.05 mmol/kg to be at least as
efficacious as any higher dose, and hypothesized that
higher doses preformed less well because of the increased
likelihood and intensity of artefacts at these doses [46].
However, in the MR-Impact study, Schwitter et al. found
better results were obtained using 0.1 mmol/kg [47].
In this meta-analysis, 18 studies were based on stress
perfusion CMR alone [10-13,15,17,19-21,24,26,31-
33,35,37,39,44], whilst the other 17 included a multi-
component examination (cine and/or late gadolinium
enhancement (LGE) and/or coronary angiography and/or
stress tagging) [14,16,18,22,23,25,27-30,34,36,38,40-43].
In their studies, Plein [22], Cury [28] and Klem [29] eval-
uated the differences in accuracy based on the sequences
evaluated and found that all studies increased accuracy
when using a combined analysis. In his study, Klem
Figure 2 Forest plot of patient-level sensitivity of stress perfusion 
CMR, compared with coronary angiography..
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sensitivity 
0  0.2  0.4  0.6  0.8  1 
Schwitter (2001)  0.86    (0.71 - 0.95) 
Doyle (2003)  0.58    (0.37 - 0.77) 
Ishida (2003)  0.90    (0.81 - 0.95) 
Nagel (2003)  0.88    (0.75 - 0.96) 
Giang (2004)  0.87    (0.69 - 0.96) 
Kawase (2004)   0.94    (0.80 - 0.99) 
Paetsch (2004)  0.91    (0.79 - 0.97) 
Plein (2004)  0.88    (0.76 - 0.95) 
Takase (2004)  0.93    (0.85 - 0.98) 
Thiele (2004)   0.75    (0.55 - 0.89) 
Plein (2005)  0.88    (0.77 - 0.95) 
Sakuma (2005)  0.81    (0.58 - 0.95) 
Cury (2006)  0.93    (0.78 - 0.99) 
Klem (2006)  0.84    (0.68 - 0.94) 
Pilz (2006)  0.96    (0.91 - 0.99) 
Merkle (2007)  0.96    (0.92 - 0.99) 
Cheng (2007)  0.90    (0.76 - 0.97) 
Greenwood (2007)  0.72    (0.53 - 0.87) 
Seeger (2007)  0.92    (0.79 - 0.98) 
Gebker (2008)  0.90    (0.80 - 0.96) 
Meyer (2008)  0.89    (0.74 - 0.97) 
Pilz (2008)  0.92    (0.73 - 0.99) 
Klein (2008)  0.87    (0.66 - 0.97) 
Klem (2008)  0.84    (0.68 - 0.94) 
Thomas (2008)  0.93    (0.76 - 0.99) 
Burgstahler (2008)    1.00    (0.63 - 1.00) 
Sensitivity (95% CI) 
Pooled Sensitivity = 0.89 (0.88 to 0.91) 
Chi-square = 55.57; df =  25 (p = 0.0004) 
Inconsistency (I-square) = 55.0 % 
Figure 3 Forest plot of patient-level specificity of stress perfusion 
CMR, compared with coronary angiography.
Specificity 
0  0.2  0.4  0.6  0.8  1 
Schwitter (2001)  0.80    (0.44 - 0.97) 
Doyle (2003)  0.78    (0.71 - 0.84) 
Ishida (2003)  0.85    (0.66 - 0.96) 
Nagel (2003)  0.90    (0.77 - 0.97) 
Giang (2004)  0.86    (0.57 - 0.98) 
Kawase (2004)   0.94    (0.71 - 1.00) 
Paetsch (2004)  0.62    (0.41 - 0.80) 
Plein (2004)  0.83    (0.52 - 0.98) 
Takase (2004)  0.85    (0.65 - 0.96) 
Thiele (2004)   0.97    (0.84 - 1.00) 
Plein (2005)  0.74    (0.52 - 0.90) 
Sakuma (2005)  0.68    (0.43 - 0.87) 
Cury (2006)  0.64    (0.35 - 0.87) 
Klem (2006)  0.58    (0.44 - 0.71) 
Pilz (2006)  0.83    (0.71 - 0.91) 
Merkle (2007)  0.72    (0.60 - 0.82) 
Cheng (2007)  0.67    (0.43 - 0.85) 
Greenwood (2007)  1.00    (0.54 - 1.00) 
Seeger (2007)  0.85    (0.55 - 0.98) 
Gebker (2008)  0.71    (0.52 - 0.86) 
Meyer (2008)  0.79    (0.58 - 0.93) 
Pilz (2008)  1.00    (0.93 - 1.00) 
Klein (2008)  0.88    (0.70 - 0.98) 
Klem (2008)  0.88    (0.80 - 0.94) 
Thomas (2008)  0.84    (0.67 - 0.95) 
Burgstahler (2008)    0.83    (0.52 - 0.98) 
Specificity (95% CI) 
Pooled Specificity = 0.80 (0.78 to 0.83) 
Chi-square = 75.13; df =  25 (p = 0.0000) 
Inconsistency (I-square) = 66.7 % Hamon et al. Journal of Cardiovascular Magnetic Resonance 2010, 12:29
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reported increased specificity (moving from 58% to 87%)
when using an algorithm interpretation (including perfu-
sion, cine and LGE).
Having access to data from different sequences (cine,
perfusion, and LGE) is especially useful when one com-
ponent shows a borderline result or is affected by image
artefacts. Most of the authors have argued that rest perfu-
sion is an important component because, in combination
with late enhancement CMR, it can help distinguish true
defects from artefacts on the stress perfusion images.
The fact that the meta-analysis demonstrated a low
NLR for stress perfusion CMR suggests that a negative
test result may in fact be more clinically useful. This is in
keeping with several reports, in different clinical settings,
of improved prognosis associated with a normal adenos-
ine stress perfusion CMR scan [48-50]. This meta-analy-
sis also demonstrated adenosine to be superior to
dipyridamole as the vasodilating stressor agent. Adenos-
ine may also be safer, with minor side effects of flushing
and headache being reported to occur more frequently
that any severe adverse effects [51]. Its shorter half life (<
10 s) is an added advantage. Moreover, adenosine has
documented safety in the context of non-ST elevation
acute coronary syndromes (in a study of 72 patients only
one demonstrated intolerance), and in recent ST eleva-
tion myocardial infarction [14,22,34].
Figure 4 Forest plot of patient-level positive likelihood ratio of 
stress perfusion CMR, compared with coronary angiography.
Positive LR 
0.01  100.0  1 
Schwitter (2001)  4.32    (1.24 - 15.03) 
Doyle (2003)  2.60    (1.68 - 4.04) 
Ishida (2003)  6.05    (2.44 - 14.99) 
Nagel (2003)  9.06    (3.55 - 23.12) 
Giang (2004)  6.07    (1.67 - 22.06) 
Kawase (2004)   15.97    (2.38 - 107.14) 
Paetsch (2004)  2.35    (1.44 - 3.86) 
Plein (2004)  5.25    (1.48 - 18.68) 
Takase (2004)  6.07    (2.46 - 14.99) 
Thiele (2004)   24.00    (3.45 - 167.16) 
Plein (2005)  3.38    (1.69 - 6.76) 
Sakuma (2005)  2.56    (1.28 - 5.13) 
Cury (2006)  2.61    (1.29 - 5.31) 
Klem (2006)  2.00    (1.42 - 2.82) 
Pilz (2006)  5.59    (3.18 - 9.84) 
Merkle (2007)  3.43    (2.38 - 4.94) 
Cheng (2007)  2.70    (1.46 - 4.99) 
Greenwood (2007)  10.03    (0.69 - 146.40) 
Seeger (2007)  5.99    (1.67 - 21.49) 
Gebker (2008)  3.10    (1.78 - 5.40) 
Meyer (2008)  4.27    (1.94 - 9.39) 
Pilz (2008)  90.00    (5.69 - 1 423.43) 
Klein (2008)  7.54    (2.57 - 22.10) 
Klem (2008)  6.91    (3.99 - 11.97) 
Thomas (2008)  5.94    (2.64 - 13.38) 
Burgstahler (2008)    4.91    (1.59 - 15.13) 
Positive LR (95% CI) 
Random Effects Model 
Pooled Positive LR = 4.18 (3.32 to 5.28) 
Cochran-Q = 59.05; df =  25 (p = 0.0001) 
Inconsistency (I-square) = 57.7 % 
Tau-squared = 0.1731 
Figure 5 Forest plot of patient-level negative likelihood ratio of 
stress perfusion CMR, compared with coronary angiography.
 
 
 
 
 
 
 
 
Negative LR 
0.01  100.0  1 
Schwitter (2001)  0.17    (0.07 - 0.40) 
Doyle (2003)  0.54    (0.34 - 0.86) 
Ishida (2003)  0.12    (0.06 - 0.24) 
Nagel (2003)  0.13    (0.06 - 0.30) 
Giang (2004)  0.16    (0.06 - 0.40) 
Kawase (2004)   0.06    (0.02 - 0.25) 
Paetsch (2004)  0.15    (0.06 - 0.37) 
Plein (2004)  0.15    (0.07 - 0.31) 
Takase (2004)  0.08    (0.03 - 0.18) 
Thiele (2004)   0.26    (0.14 - 0.49) 
Plein (2005)  0.16    (0.08 - 0.34) 
Sakuma (2005)  0.28    (0.11 - 0.71) 
Cury (2006)  0.10    (0.03 - 0.42) 
Klem (2006)  0.28    (0.13 - 0.60) 
Pilz (2006)  0.04    (0.02 - 0.11) 
Merkle (2007)  0.05    (0.02 - 0.12) 
Cheng (2007)  0.15    (0.06 - 0.40) 
Greenwood (2007)  0.31    (0.17 - 0.56) 
Seeger (2007)  0.09    (0.03 - 0.28) 
Gebker (2008)  0.14    (0.07 - 0.29) 
Meyer (2008)  0.14    (0.05 - 0.36) 
Pilz (2008)  0.10    (0.03 - 0.33) 
Klein (2008)  0.15    (0.05 - 0.43) 
Klem (2008)  0.18    (0.09 - 0.39) 
Thomas (2008)  0.08    (0.02 - 0.32) 
Burgstahler (2008)    0.07    (0.00 - 1.03) 
Negative LR (95% CI) 
Random Effects Model 
Pooled Negative LR = 0.15 (0.11 to 0.19) 
Cochran-Q = 62.47; df =  25 (p = 0.0000) 
Inconsistency (I-square) = 60.0 % 
Tau-squared = 0.2723 
Figure 6 Plot of symmetric summary receiver operating curve 
characteristic of stress perfusion CMR, compared with coronary 
angiography. The receiver operator characteristic curve provides a 
graphical display of diagnostic accuracy by plotting 1-specificity in the 
horizontal axis and sensitivity in the vertical axis. The pertinent area un-
der the curve (AUC) and the Q* statistic (the point where sensitivity 
and specificity are maximized), both with standard errors (SE), are also 
included.
0  0.2  0.4  0.6  0.8  1  0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
0.8 
0.9 
1 
Symmetric SROC 
AUC = 0.9232 
SE(AUC) = 0.0131 
Q* = 0.8571 
SE(Q*) = 0.0152 
SROC Curve 
1-specificity 
Sensitivity 
Figure 7 Plots of symmetric summary receiver operating curve 
characteristic of stress perfusion CMR, compared with coronary 
angiography for adenosine and dipyridamole stressors.
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From this analysis, visual assessment of stress perfusion
CMR provided a higher sensitivity but a lower specificity
than semi-quantitative assessment. Currently there is no
consensus on the superiority of visual over semi-quanti-
tative assessment, or on which method of semi-quantita-
tive assessment should be used. However, the drawbacks
of semi-quantitative assessment are that it is more time-
consuming, hence not ideal for day-to-day clinical pur-
poses, and the lack of any homogeneous post-processing
protocols. Therefore, visual assessment is currently the
method most often used in routine clinical practice.
Only 4 studies were performed using 3T CMR, which
provides improved resolution [32,38,39,43]. Enhanced
sensitivity has been reported [32] and attributed to the
higher signal-to-noise and contrast-to-noise ratios per-
mitting improved detection of endocardial perfusion
defects. Although most authors argue that the increased
prevalence of dark rim artefacts at these higher field
strengths (ranging from 8 up to 82%) does not hamper
myocardial perfusion analysis [32,39,43], Gebker dis-
agrees and suggests they could limit specificity by
increasing false positive rates [38]. In this analysis, 3T
CMR was also found to have a decreased specificity, indi-
cating that higher false positive rates may be a real prob-
lem. Further studies will be necessary if this controversy
is to be resolved.
The results of the per- territory-based analysis showed
the anticipated decrease in sensitivity and increase in
specificity seen when moving from the level of the patient
to that of the coronary territory. Among the 8 studies that
performed a coronary-artery level analysis, stress perfu-
sion CMR had a higher sensitivity for detection of signifi-
cant coronary disease in the LAD artery, compared with
the CX and RCA. A possible explanation for this finding
may have been the use of a surface radiofrequency coil,
which led to lower signal intensities in the more distant
inferior and lateral segments.
Study limitations
Although conventional CA is the established technique
for diagnosing significant CAD in routine clinical prac-
tice, it remains an imperfect reference standard due to its
inability to evaluate the hemodynamic significance of a
stenosis.
Substantial inter-study heterogeneity in multiple per-
formance characteristics were observed. Therefore, the
pooled performance indices and their interpretation have
to be treated with a degree of caution, even though the
random-effects model used throughout the analysis
should have compensated for this. The observed hetero-
geneity may have been due to variations in: (i) the image
acquisition technique (MR scanner manufacturer, 1.5T or
3T field strengths, pulse sequence, number of slices, con-
trast dose and rate of infusion); (ii) the interpretation
method (visual or semi-quantitative, post-processing
techniques); (iii) the patient selection criteria (exclusion
or inclusion of patients with prior myocardial infarction,
patient populations with differing prevalence of CAD);
and (iv) in the definition of significant obstructive CAD
(50% or 70%). We noticed, as expected, that studies which
performed analysis for 50% and for 70% coronary artery
stenosis thresholds, reported an increased sensitivity and
a decreased specificity when moving thresholds from 50%
to 70% [29,33,36].
These general limitations of stress perfusion CMR
could be addressed in future multi-centre studies if stan-
dardized imaging protocols, post-processing techniques
and patient selection criteria are employed.
Conclusion
Stress Perfusion CMR has a high sensitivity and moderate
specificity for the diagnosis of significant obstructive
CAD compared with CA in patients with a high preva-
lence of the disease.
Future technical developments that increase spatial and
temporal resolution whilst reducing artefacts may further
improve the diagnostic performance of stress perfusion
CMR, and in particular improve its specificity [32]. Cur-
rently, however, the low NLR makes stress perfusion
CMR particularly accurate and useful in ruling out signif-
icant CAD.
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